Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis : A Randomized Controlled Trial
- PMID: 34843380
- DOI: 10.7326/M21-1962
Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis : A Randomized Controlled Trial
Abstract
Background: Weight loss improves fatty liver disease. No randomized trial has compared the effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) on liver fat content and fibrosis.
Objective: To compare the 1-year effects of SG and RYGB on hepatic steatosis and fibrosis.
Design: Single-center, randomized, controlled trial (Oseberg [ObesitySurgery in Tønsberg]). (ClinicalTrials.gov: NCT01778738).
Setting: Tertiary care obesity center in Norway.
Participants: 100 patients (65% female; mean age, 47.5 years; mean body mass index, 42 kg/m2) with type 2 diabetes mellitus (T2DM).
Intervention: From January 2013 to February 2018, patients were randomly assigned (1:1 ratio) to SG or RYGB.
Measurements: The primary outcome was remission of T2DM (previously published). Predefined secondary outcomes in the present study were hepatic steatosis and fibrosis assessed by magnetic resonance imaging (liver fat fraction), enhanced liver fibrosis (ELF) test, noninvasive indices, and liver enzymes.
Results: Liver fat fraction declined similarly after SG (-19.7% [95% CI, -22.5% to -16.9%]) and RYGB (-21.5% [CI, -24.3% to -18.6%]) from surgery to 1-year follow-up, and almost all patients (SG, 94%; RYGB, 100%) had no or low-grade steatosis at 1 year. The ELF score category remained stable in 77% of patients, but 18% experienced worsening of fibrosis at 1 year, with no substantial between-group difference.
Limitations: Single-center study, short follow-up time, and lack of power for secondary outcomes.
Conclusion: With an almost complete clearance of liver fat 1 year after surgery, RYGB and SG were both highly effective in reducing hepatic steatosis. Bariatric surgery had less influence on degree of fibrosis in the short term, but assessment of long-term progression is warranted.
Primary funding source: Vestfold Hospital Trust and the South-Eastern Norway Regional Health Authority.
Comment in
-
Further Insights Into the Impact of Bariatric Surgery on the Progression of Nonalcoholic Fatty Liver Disease.Gastroenterology. 2022 Aug;163(2):528-529. doi: 10.1053/j.gastro.2022.06.007. Epub 2022 Jun 7. Gastroenterology. 2022. PMID: 35688181 No abstract available.
Similar articles
-
Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial.Lancet Diabetes Endocrinol. 2019 Dec;7(12):912-924. doi: 10.1016/S2213-8587(19)30344-4. Epub 2019 Oct 31. Lancet Diabetes Endocrinol. 2019. PMID: 31678062 Clinical Trial.
-
Long-term follow-up after sleeve gastrectomy versus Roux-en-Y gastric bypass versus one-anastomosis gastric bypass: a prospective randomized comparative study of weight loss and remission of comorbidities.Surg Endosc. 2019 Feb;33(2):401-410. doi: 10.1007/s00464-018-6307-9. Epub 2018 Jun 25. Surg Endosc. 2019. Retraction in: Surg Endosc. 2021 Mar;35(3):1492. doi: 10.1007/s00464-021-08298-0 PMID: 29943058 Retracted. Clinical Trial.
-
Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial.Lancet Diabetes Endocrinol. 2023 Aug;11(8):555-566. doi: 10.1016/S2213-8587(23)00127-4. Epub 2023 Jul 3. Lancet Diabetes Endocrinol. 2023. PMID: 37414071 Clinical Trial.
-
Remission of Type 2 Diabetes Mellitus (T2DM) after Sleeve Gastrectomy (SG), One-Anastomosis Gastric Bypass (OAGB), and Roux-en-Y Gastric Bypass (RYGB): A Systematic Review.Medicina (Kaunas). 2023 May 19;59(5):985. doi: 10.3390/medicina59050985. Medicina (Kaunas). 2023. PMID: 37241216 Free PMC article. Review.
-
Surgery for weight loss in adults.Cochrane Database Syst Rev. 2014 Aug 8;2014(8):CD003641. doi: 10.1002/14651858.CD003641.pub4. Cochrane Database Syst Rev. 2014. PMID: 25105982 Free PMC article. Review.
Cited by
-
Bariatric-induced microbiome changes alter MASLD development in association with changes in the innate immune system.Front Microbiol. 2024 Aug 9;15:1407555. doi: 10.3389/fmicb.2024.1407555. eCollection 2024. Front Microbiol. 2024. PMID: 39184030 Free PMC article.
-
New mechanistic insights of anti-obesity by sleeve gastrectomy-altered gut microbiota and lipid metabolism.Front Endocrinol (Lausanne). 2024 Feb 2;15:1338147. doi: 10.3389/fendo.2024.1338147. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38375198 Free PMC article.
-
Safety and Efficacy of LSG Versus LRYGB on Patients with Obesity: a Systematic Review and Meta-analysis from RCTs.Obes Surg. 2024 Apr;34(4):1138-1151. doi: 10.1007/s11695-024-07076-w. Epub 2024 Feb 14. Obes Surg. 2024. PMID: 38351200
-
MASLD treatment-a shift in the paradigm is imminent.Front Med (Lausanne). 2023 Dec 11;10:1316284. doi: 10.3389/fmed.2023.1316284. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38146424 Free PMC article. Review.
-
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association.Diabetes Metab J. 2023 Sep;47(5):575-594. doi: 10.4093/dmj.2023.0282. Epub 2023 Sep 26. Diabetes Metab J. 2023. PMID: 37793979 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials